A Non-dispensing Fit Evaluation of Investigational Limbal Ring Soft Contact Lenses With Polyvinylpyrrolidone (PVP) in Asian Eyes
NCT ID: NCT02036320
Last Updated: 2018-06-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
190 participants
INTERVENTIONAL
2014-01-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Multifocal Contact Lens on Ocular Tissue
NCT02345720
Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP)
NCT01180777
Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Manufacturing Technology
NCT03962790
Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens
NCT01484028
Clinical Evaluation of Daily Disposable Contact Lenses
NCT02097030
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
etafilcon A with additive printed limbal ring
Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
etafilcon A
Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
etafilcon A
Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
etafilcon A
Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
etafilcon A
Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.
3. The subject must be an Asian female (self-reported).
4. The subject must be at least 18 years old and less than 41 years old.
5. The subject must meet two of the four East Asian anatomical categories (Appendix D) and have a prominent epicanthic fold to be classified East Asian ethnicity. For the purpose of this protocol, East Asian ethnicities may include: China, Japan, Korea, Taiwan, Vietnam, Hong Kong, Malaysia, and Singapore but are not inclusive of these regions.
6. The subject must be a habitual soft contact lens wearer. Habitual is defined as: at least one month of daily wear where the lenses are worn a minimum of six (6) hours per day and a minimum of three (3) days per week prior to enrollment in the study.
7. The subject's optimal non-vertexed spherical equivalent distance correction (based on their optimal sphero-cylinder refraction) must be between +2.00 D and -12.00 D.
8. Any cylinder power must be less than or equal to -1.00 D confirmed by refraction.
9. The subject must possess a functional/usable pair of spectacles and wear them to the visit (only if applicable-to the investigator's discretion).
10. The subject's best correctable visual acuity is 20/40 or better (OD and OS) at the baseline visit.
Exclusion Criteria
2. Ocular or systemic disease which might interfere with contact lens wear.
3. Any known hypersensitivity or allergic reaction to contact lenses or contact lens solutions.
4. Use of any ocular or topical medication.
5. Use of any systemic (oral) medication that is taken for an ocular condition which might interfere with contact lens wear.
6. Use of any systemic (oral) medication that is taken for a systemic condition which might interfere with the contact lens wear (this determination will be at the discretion of the investigator).
7. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities, bulbar injection or any other abnormalities of the cornea and/or conjunctiva which would contraindicate contact lens wear.
8. Rigid gas permeable or hybrid design (rigid gas permeable center and a soft lens skirt) contact lens wear within the past 30 days.
9. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia.
10. Any previous or planned (during duration of the study), ocular or intraocular surgery (e.g. radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), peripheral iridotomy, etc.)
11. Pregnancy or lactation.
12. Diabetes.
13. Infectious disease.
14. Habitual contact lens type is multifocal, monovision or worn as extended wear.
15. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
16. Suspicion of or recent history od alcohol or substance abuse.
17. History of serious mental illness.
18. History of seizures.
19. Employee or family member of the investigational clinic (e.g. Investigator, Coordinator, Technician).
18 Years
41 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Berkeley, California, United States
Fullerton, California, United States
New York, New York, United States
Cleveland, Ohio, United States
Dallas, Texas, United States
Houston, Texas, United States
Waterloo, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-5477
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.